Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News [Yahoo! Finance]
Zenas BioPharma, Inc. (ZBIO)
Company Research
Source: Yahoo! Finance
Disease, a late stage clinical milestone that puts regulatory and commercialization questions front and center for investors. See our latest analysis for Zenas BioPharma. The INDIGO update comes after a volatile stretch, with a 1 day share price return of 23.01% and a 7 day share price return of 30.13%, following a 30 day share price return decline of 51.27%. The 1 year total shareholder return of 146.63% points to strong longer term momentum off a lower base. If you are looking at how clinical news can reshape opportunities across the sector, this could be a useful cue to scan other healthcare stocks that may fit your watchlist next. With Zenas shares rebounding sharply after the INDIGO readout but still down over the past quarter and year to date, you have to ask: is the market underestimating the opportunity here, or already pricing in future growth? At the last close of US$19.78, Zenas BioPharma trades on a P/B of 5.4x. This screens as expensive compared with both peers
Show less
Read more
Impact Snapshot
Event Time:
ZBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZBIO alerts
High impacting Zenas BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
ZBIO
News
- Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIOGlobeNewswire
- Zenas BioPharma (NASDAQ:ZBIO) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ZBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
ZBIO
Earnings
- 11/12/25 - Miss
ZBIO
Sec Filings
- 1/14/26 - Form SCHEDULE
- 1/9/26 - Form 4
- 12/19/25 - Form S-8
- ZBIO's page on the SEC website